Arjun Ravishankar, MBBS
Clinical FellowAbout
Research
Publications
Featured Publications
Epigenetic memory of coronavirus infection in innate immune cells and their progenitors
Cheong J, Ravishankar A, Sharma S, Parkhurst C, Grassmann S, Wingert C, Laurent P, Ma S, Paddock L, Miranda I, Karakaslar E, Nehar-Belaid D, Thibodeau A, Bale M, Kartha V, Yee J, Mays M, Jiang C, Daman A, Martinez de Paz A, Ahimovic D, Ramos V, Lercher A, Nielsen E, Alvarez-Mulett S, Zheng L, Earl A, Yallowitz A, Robbins L, LaFond E, Weidman K, Racine-Brzostek S, Yang H, Price D, Leyre L, Rendeiro A, Ravichandran H, Kim J, Borczuk A, Rice C, Jones R, Schenck E, Kaner R, Chadburn A, Zhao Z, Pascual V, Elemento O, Schwartz R, Buenrostro J, Niec R, Barrat F, Lief L, Sun J, Ucar D, Josefowicz S. Epigenetic memory of coronavirus infection in innate immune cells and their progenitors. Cell 2023, 186: 3882-3902.e24. PMID: 37597510, PMCID: PMC10638861, DOI: 10.1016/j.cell.2023.07.019.Peer-Reviewed Original Research
2026
Breaking the Immune Sanctuary: Targeting Metastatic Niches.
Ravishankar A, Ramamoorthi G, Weiss T, Le Rhun E, Czerniecki B, Sundar R. Breaking the Immune Sanctuary: Targeting Metastatic Niches. American Society Of Clinical Oncology Educational Book 2026, 46: e517520. PMID: 42208002, DOI: 10.1200/edbk-26-517520.Peer-Reviewed Original ResearchConceptsdisseminated cancer cellschimeric antigen receptor T cellsformation of premetastatic nichesstereotactic body radiation therapysuppressive myeloid cellshyperthermic intraperitoneal chemotherapytumor-derived factorsTh1-mediated immunityclinical trial designfibrovascular changeslocoregional interventionssystemic immunotherapyintraperitoneal chemotherapyradiation therapyintratumoral deliverymetastatic nichepremetastatic nichedendritic cellsimmune surveillancemyeloid cellsclonal evolutionclinical hurdlesliquid biopsysystemic agentscancer deathPlatelet proteomics on less than a drop of previously frozen, non-citrate plasma
Tabang D, Korff K, Brannon K, Tilburg J, Mandal K, Viodé A, van Zalm P, Ravishankar A, Cheong J, Schott O, Arnaout R, Josefowicz S, Italiano J, Steen H, Smolen K. Platelet proteomics on less than a drop of previously frozen, non-citrate plasma. Molecular Omics 2026, 22: aaiag017. PMID: 42059667, DOI: 10.1093/molecular-omics/aaiag017.Peer-Reviewed Original ResearchHow We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas
Ravishankar A, Somaya V, Qureshi H, Kiwan A, Montanari F, Girardi M, Foss F, Sethi T. How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas. Cancers 2026, 18: 965. PMID: 41899567, PMCID: PMC13024611, DOI: 10.3390/cancers18060965.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThis study investigates diagnostic and treatment strategies for mature T-cell leukemias, emphasizing tailored approaches for subtypes like T-PLL, ATLL, T-LGL, and Sézary syndrome.
2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes
Nassar A, El Zarif T, Khalid A, Rahme S, Zhong C, Kwak L, Salame M, Farhat E, Freeman D, El-Am E, Ravishankar A, Ahmad B, Nana F, Kaldas D, Naqash A, Sharon E, LeBoeuf N, Cortellini A, Malgeri A, Gupta S, Al-Hader A, Sparks J, Linnoila J, Hamnvik O, Mouhieddine T, Marron T, Parikh K, McKay R, Dilling T, Choueiri T, Adib E, Najem E, Kim S, Sonpavde G. Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes. Journal For ImmunoTherapy Of Cancer 2024, 12: e008724. PMID: 38448038, PMCID: PMC10916116, DOI: 10.1136/jitc-2023-008724.Peer-Reviewed Original ResearchConceptstreatment-related adverse eventsimmune checkpoint inhibitorstime to next treatmentnon-small cell lung cancerimmune checkpoint inhibitor initiationparaneoplastic syndromeoverall survivalcohort 1checkpoint inhibitorssolid tumorspatients treated with immune checkpoint inhibitorsinterruption of ICIsmetastatic non-small cell lung cancersafety of immune checkpoint inhibitorstreated with immune checkpoint inhibitorstype of immune checkpoint inhibitorcohort 2immune checkpoint inhibitor therapyKaplan-Meier methodcell lung cancertime to exacerbationconcurrent chemotherapyICI initiationimmunosuppressive therapymedian age
2023
Fungal microbiota sustains lasting immune activation of neutrophils and their progenitors in severe COVID-19
Kusakabe T, Lin W, Cheong J, Singh G, Ravishankar A, Yeung S, Mesko M, DeCelie M, Carriche G, Zhao Z, Rand S, Doron I, Putzel G, Worgall S, Cushing M, Westblade L, Inghirami G, Parkhurst C, Guo C, Schotsaert M, García-Sastre A, Josefowicz S, Salvatore M, Iliev I. Fungal microbiota sustains lasting immune activation of neutrophils and their progenitors in severe COVID-19. Nature Immunology 2023, 24: 1879-1889. PMID: 37872315, PMCID: PMC10805066, DOI: 10.1038/s41590-023-01637-4.Peer-Reviewed Original ResearchSex Differences in Clinical Presentation and Management in Eosinophilic Esophagitis
Fogla R, Glaubitz E, Bhatia S, Ravishankar A, Andy C, Niec R, Katz P. Sex Differences in Clinical Presentation and Management in Eosinophilic Esophagitis. Foregut The Journal Of The American Foregut Society 2023, 3: 141-148. DOI: 10.1177/26345161231170590.Peer-Reviewed Original Research
2022
Angiopoietin 2 Is Associated with Vascular Necroptosis Induction in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome
Price D, Benedetti E, Hoffman K, Gomez-Escobar L, Alvarez-Mulett S, Capili A, Sarwath H, Parkhurst C, Lafond E, Weidman K, Ravishankar A, Cheong J, Batra R, Büyüközkan M, Chetnik K, Easthausen I, Schenck E, Racanelli A, Outtz Reed H, Laurence J, Josefowicz S, Lief L, Choi M, Schmidt F, Borczuk A, Choi A, Krumsiek J, Rafii S. Angiopoietin 2 Is Associated with Vascular Necroptosis Induction in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome. American Journal Of Pathology 2022, 192: 1001-1015. PMID: 35469796, PMCID: PMC9027298, DOI: 10.1016/j.ajpath.2022.04.002.Peer-Reviewed Original ResearchPublisher Correction: Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability
Guo P, Liu Y, Geng F, Daman A, Liu X, Zhong L, Ravishankar A, Lis R, Barcia Durán J, Itkin T, Tang F, Zhang T, Xiang J, Shido K, Ding B, Wen D, Josefowicz S, Rafii S. Publisher Correction: Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nature Cell Biology 2022, 24: 279-279. PMID: 35058593, DOI: 10.1038/s41556-022-00851-w.Commentaries, Editorials and Letters
2021
Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability
Guo P, Liu Y, Geng F, Daman A, Liu X, Zhong L, Ravishankar A, Lis R, Barcia Durán J, Itkin T, Tang F, Zhang T, Xiang J, Shido K, Ding B, Wen D, Josefowicz S, Rafii S. Histone variant H3.3 maintains adult haematopoietic stem cell homeostasis by enforcing chromatin adaptability. Nature Cell Biology 2021, 24: 99-111. PMID: 34961794, PMCID: PMC9166935, DOI: 10.1038/s41556-021-00795-7.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCD8-Positive T-LymphocytesCell Cycle ProteinsCell LineChromatinGranulocytesHematopoiesisHematopoietic Stem CellsHistone ChaperonesHistonesHuman Umbilical Vein Endothelial CellsHumansMacrophagesMethylationMiceMice, Inbred C57BLMice, KnockoutMyelopoiesisPromoter Regions, GeneticProtein Processing, Post-TranslationalTranscription FactorsConceptshaematopoietic stem cellsinterferon regulatory factor familyH3K9me3 markhistone variantschromatin adaptersfamily of transcription factorsLoss of H3.3histone variant H3.3H3 histone variantlineage-specific genespost-translational modificationshaematopoietic stem cell homeostasisstem cell homeostasisinterferon regulatory factor family of transcription factorsbivalent geneschaperone HIRAgranulocyte-macrophage progenitorsvariant H3.3H3K27me3 markpromoter regiontranscription factorsH3.3mammalian systemsexpression of stemnesscell homeostasis